Transcription factor SP1 is a member of the Kruppel-like factor that has been shown to be overexpressed in several cancer types, including cervical cancer, and is associated with poor prognosis when overexpressed; assessing the impact of SP1 on tumor progression in cervical cancer was the aim of a recently published study by Wenzhou Medical University investigators.
Researchers from Nanjing University of Traditional Chinese Medicine reported the discovery and preclinical characterization of fluorine-substituted selective estrogen receptor degraders (SERDs) as potential candidates for the treatment of estrogen receptor (ER)-positive breast cancer.
Despite advances in diagnosis and treatment, cardiovascular disease remains the leading cause of death worldwide. Single-nucleotide polymorphisms (SNPs) in microRNAs are known to play important roles in acute coronary syndrome (ACS). MicroRNA 146a (miR-146a) is significantly upregulated in human atherosclerotic plaques and its circulating levels are elevated in patients with ACS, and was thus the focus of a recent study.
Trueline Therapeutics Inc., a subsidiary of Anji Pharmaceuticals Inc., has successfully completed IND-enabling studies with Mcl-1 inhibitor TTX-810, a highly potent and selective macrocyclic compound to treat patients with solid tumor or hematological cancers. The company is now on track to initiate clinical development.
PARP14 is an ADP-ribosyltransferase that transfers ADP-ribose from NAD+ onto the appropriate protein target. PARP14 selectively binds to STAT6 and promotes expression of IL-4-regulated genes, thus modulating inflammatory signaling pathways. PARP14 is overexpressed in tissues from patients with dermatomyositis, atopic dermatitis, psoriasis and other inflammatory disorder cells compared to normal tissues.
By analyzing gene expression patterns in the placenta of nearly 150 pregnancies and comparing them to fetal gene expression in the brain, researchers from the Lieber Institute for Brain Development have gained new insights into the importance of placental tissue in setting the risk trajectory for the development of schizophrenia. The work was published in Nature Communications on May 15, 2023.
New and updated preclinical data presented at the American Society of Gene & Cell Therapy Congress in Los Angeles, by: Abeona Therapeutics, Arsenal Biosciences, Cimeio Therapeutics, Homology Medicines, Locanabio, Precision Biosciences, Wave Life Sciences.
Haisco Pharmaceutical Group Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon binding moiety covalently coupled to poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) targeting moiety through a linker acting as PARP-1 degradation inducers reported to be useful for the treatment of cancer.
RSS
